Compare Cadila Healthcare with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs PIRAMAL ENTERPRISES - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE PIRAMAL ENTERPRISES CADILA HEALTHCARE/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 19.8 15.5 127.8% View Chart
P/BV x 2.7 1.0 257.5% View Chart
Dividend Yield % 1.3 1.7 75.6%  

Financials

 CADILA HEALTHCARE   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-19
PIRAMAL ENTERPRISES
Mar-19
CADILA HEALTHCARE/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs4323,303 13.1%   
Low Rs3061,797 17.1%   
Sales per share (Unadj.) Rs128.6716.5 17.9%  
Earnings per share (Unadj.) Rs18.579.7 23.3%  
Cash flow per share (Unadj.) Rs24.4107.9 22.6%  
Dividends per share (Unadj.) Rs3.5028.00 12.5%  
Dividend yield (eoy) %0.91.1 86.3%  
Book value per share (Unadj.) Rs101.51,477.5 6.9%  
Shares outstanding (eoy) m1,023.74184.45 555.0%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x2.93.6 80.7%   
Avg P/E ratio x19.932.0 62.3%  
P/CF ratio (eoy) x15.123.6 64.1%  
Price / Book Value ratio x3.61.7 211.0%  
Dividend payout %18.935.1 53.7%   
Avg Mkt Cap Rs m378,170470,292 80.4%   
No. of employees `00012.47.8 159.1%   
Total wages/salary Rs m21,24122,504 94.4%   
Avg. sales/employee Rs Th10,585.016,899.4 62.6%   
Avg. wages/employee Rs Th1,707.82,877.7 59.3%   
Avg. net profit/employee Rs Th1,526.51,879.9 81.2%   
INCOME DATA
Net Sales Rs m131,656132,153 99.6%  
Other income Rs m2,0113,128 64.3%   
Total revenues Rs m133,667135,281 98.8%   
Gross profit Rs m29,73166,290 44.9%  
Depreciation Rs m5,9865,202 115.1%   
Interest Rs m1,93544,097 4.4%   
Profit before tax Rs m23,82120,119 118.4%   
Minority Interest Rs m4693,194 14.7%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,3038,611 61.6%   
Profit after tax Rs m18,98714,701 129.2%  
Gross profit margin %22.650.2 45.0%  
Effective tax rate %22.342.8 52.0%   
Net profit margin %14.411.1 129.6%  
BALANCE SHEET DATA
Current assets Rs m84,981122,742 69.2%   
Current liabilities Rs m73,425310,810 23.6%   
Net working cap to sales %8.8-142.3 -6.2%  
Current ratio x1.20.4 293.1%  
Inventory Days Days7523 323.1%  
Debtors Days Days11039 282.0%  
Net fixed assets Rs m133,493116,904 114.2%   
Share capital Rs m1,024369 277.6%   
"Free" reserves Rs m102,839272,161 37.8%   
Net worth Rs m103,863272,530 38.1%   
Long term debt Rs m39,497270,196 14.6%   
Total assets Rs m234,831856,261 27.4%  
Interest coverage x13.31.5 914.0%   
Debt to equity ratio x0.41.0 38.4%  
Sales to assets ratio x0.60.2 363.3%   
Return on assets %8.96.9 129.7%  
Return on equity %18.35.4 338.9%  
Return on capital %18.312.4 147.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m48,40415,200 318.4%   
Fx outflow Rs m11,5934,889 237.1%   
Net fx Rs m36,81110,312 357.0%   
CASH FLOW
From Operations Rs m28,823-115,975 -24.9%  
From Investments Rs m-57,387-8,265 694.3%  
From Financial Activity Rs m18,846107,525 17.5%  
Net Cashflow Rs m-7,105-16,650 42.7%  

Share Holding

Indian Promoters % 74.8 52.9 141.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 4.0 207.5%  
FIIs % 5.9 26.6 22.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 16.5 66.7%  
Shareholders   44,069 93,274 47.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   NOVARTIS  TORRENT PHARMA  STRIDES PHARMA SCIENCE  CIPLA  ASTRAZENECA PHARMA  

Compare CADILA HEALTHCARE With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Scales 42,000 and Smallcaps Rebound: What Happens Next?(Podcast)

This week, the BSE Sensex crossed 42,000 level for the first time. While Nifty followed suit, hitting a record high of 12,377.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (2QFY20); Net Profit Up 16.5% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 16.5% YoY). Sales on the other hand came in at Rs 36 bn (up 14.6% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY20); Net Profit Up 390.0% (Quarterly Result Update)

Aug 1, 2019 | Updated on Aug 1, 2019

For the quarter ended June 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (up 390.0% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 9, 2019 | Updated on Jul 9, 2019

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

More Views on News

Most Popular

My Latest Stock Recommendation(Fast Profits Daily)

Jan 10, 2020

The story behind my latest stock recommendation and an important announcement.

Saffron Curtain = Hindutva Rate of Growth?(The Honest Truth)

Jan 8, 2020

Will the Indian economy revert to a sub-3% growth rate?

Multibaggers of the Next Decade(The 5 Minute Wrapup)

Jan 6, 2020

The one key ingredient to be seen amongst top multibaggers of the next decade

Your Safe Income Options for 2020(Fast Profits Daily)

Jan 9, 2020

What are you safest investing options in 2020 when interest rates fall.

I Made a Killing in the Markets this Week... Here's How(Profit Hunter)

Jan 10, 2020

How we made a killing in the markets amidst geopolitical tension and war mongering.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Jan 17, 2020 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE - STRIDES PHARMA SCIENCE COMPARISON

COMPARE CADILA HEALTHCARE WITH

MARKET STATS